Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug-naive patients: A case for specific, low potency D-2 antagonists

Lambert, T., Keks, N., McGrath, J., Catts, S., Hustig, H., Vaddadi, K., Burrows, G., Varghese, F., George, T., Kerr, K., Johnson, G., Burnett, P., Zorbas, A., Hill, C. and Copolov, D. (1995) Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug-naive patients: A case for specific, low potency D-2 antagonists. Human Psychopharmacology, 10 6: 455-460. doi:10.1002/hup.470100604


Author Lambert, T.
Keks, N.
McGrath, J.
Catts, S.
Hustig, H.
Vaddadi, K.
Burrows, G.
Varghese, F.
George, T.
Kerr, K.
Johnson, G.
Burnett, P.
Zorbas, A.
Hill, C.
Copolov, D.
Title Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug-naive patients: A case for specific, low potency D-2 antagonists
Journal name Human Psychopharmacology   Check publisher's open access policy
ISSN 0885-6222
1099-1077
Publication date 1995-11
Sub-type Article (original research)
DOI 10.1002/hup.470100604
Volume 10
Issue 6
Start page 455
End page 460
Total pages 6
Place of publication Bognor Regis, West Sussex, United Kingdom
Publisher John Wiley & Sons
Language eng
Formatted abstract
Remoxipride, a substituted benzamide, is a selective D2 antagonist with an atypical neuroleptic profile. Previous studies have demonstrated its antipsychotic efficacy against haloperidol and, more recently, thioridazine. Of the 144 patients enrolled in the Australian remoxipride-thioridazine comparative trial, 28 presented for their first episode of schizophrenia and/or had no previous neuroleptic treatment. These patients form the subject of this paper. The study found that in persons presenting for their first admission for schizophrenia, remoxipride showed equal antipsychotic efficacy compared to thioridazine. Treatments were comparable in terms of generating few extrapyramidal symptoms but thioridazine caused more significant general side-effects. Patients are more likely to be compliant with remoxipride due to its tolerability. Despite remoxipride being withdrawn from the market due to a suggested association with aplastic anaemia, this class of substituted benzamides warrants further examination as a treatment agent for first and subsequent episodic psychosis.
Keyword Drug therapy
Neuroleptic drugs
Remoxipride
Schizophrenia
Side-effects (drug)
Thioridazine
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 09 Mar 2011, 15:34:42 EST